UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 4)*

	a Pharmaceuticals, Inc.
(Name of Is	ssuer)
	k, par value \$.10 per share
(Title of Class of	
	94100
(CUSIP Numbe Dece	ember 31, 2012
(Date of Event Which Require	
Check the appropriate box to designate the r Schedule is filed:	rule pursuant to which this
[X] Rule 13d-1(b)	
[_] Rule 13d-1(c)	
[_] Rule 13d-1(d)	
*The remainder of this cover page shall be finitial filing on this form with respect to and for any subsequent amendment containing the disclosures provided in a prior cover p	o the subject class of securities, g information which would alter
The information required in the remainder of deemed to be "filed" for the purpose of Sect Act of 1934 ("Act") or otherwise subject to of the Act but shall be subject to all other see the Notes).	tion 18 of the Securities Exchange the liabilities of that section provisions of the Act (however,
CUSIP NO. 090694100 13G	Page 2 of 8 Pages
(1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE F	
Renaissance Technologies LLC 26-6	0385758
(2) CHECK THE APPROPRIATE BOX IF A MEMBER ((a) [_] (b) [_]	OF A GROUP (SEE INSTRUCTIONS):
(3) SEC USE ONLY	
(4) CITIZENSHIP OR PLACE OF ORGANIZATION	
Delaware	
	(5) SOLE VOTING POWER
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	304, 405
	(6) SHARED VOTING POWER
	0
	(7) SOLE DISPOSITIVE POWER
	304,405

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EA	CH REPORTING PERSON	
304,421		
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (SEE INSTRUCTIONS)	(9) EXCLUDES CERTAIN SHARES	
	[_]	
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
1.08 %		
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA		
Page 2 of 8 pages		
Page 3 of 8 pa	ges	
CUSIP NO. 090694100 13G	Page 3 of 8 Pages	
(1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERS		
RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734		
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_]		
(3) SEC USE ONLY		
(4) CITIZENSHIP OR PLACE OF ORGANIZATION		
Delaware		
	(5) SOLE VOTING POWER	
NUMBER OF SHARES BENEFICIALLY OWNED	304,405	
BY EACH REPORTING PERSON WITH:	(6) SHARED VOTING POWER	
	0	
	(7) SOLE DISPOSITIVE POWER	
	304,405	
	(8) SHARED DISPOSITIVE POWER	
	16	
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
304,421		
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
1.08 %		
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC		
Page 3 of 8 nages		

CUSIP NO. 090694100 13G Page 4 of 8 Pages

Item 1.

(a) Name of Issuer

Biota Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices.

12270 Wilkins Avenue, Rockville, MD 20852

Item 2.

(a) Name of Person Filing:

This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").

(b) Address of Principal Business Office or, if none, Residence.

The principal business address of the reporting persons is:

800 Third Avenue New York, New York 10022

(c) Citizenship.

RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.

(d) Title of Class of Securities.

common stock, par value \$.10 per share

(e) CUSIP Number.

090694100

Page 4 of 8 pages

Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c), check whether the person filing is a:

- (a) $[_]$ Broker or dealer registered under section 15 of the Act.
- (b) [_] Bank as defined in section 3(a)(6) of the Act.
- (c) [_] Insurance Company as defined in section 3(a)(19) of the Act.
- (d) [_] Investment Company registered under section 8 of the Investment Company Act.
- (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E).
- (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G).
- (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
- (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

(a) Amount beneficially owned.

RTC: 304,421 shares

RTHC: 304,421 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC.

(b) Percent of Class.

RTC: 1.08 % RTHC: 1.08 %

- (c) Number of shares as to which the person has:
 - (i) sole power to vote or to direct the vote:

RTC: 304,405 RTHC: 304,405 (ii) Shared power to vote or to direct the vote:

(iii) sole power to dispose or to direct the disposition of:

RTC: 304,405 RTHC: 304,405

(iv) Shared power to dispose or to direct the disposition of:

RTC: 16 RTHC: 16

Page 5 of 8 pages

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable

Item 8. Identification and Classification of Members of the Group.

Not applicable

Item 9. Notice of Dissolution of a Group.

Not applicable

Page 6 of 8 pages

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2013

Renaissance Technologies LLC

By: Mark Silber Executive Vice President

Renaissance Technologies Holdings Corporation

By: Mark Silber Vice President

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

Page 7 of 8 Pages

EXHIBIT 99.1

AGREEMENT REGARDING JOINT FILING

UNDER RULE 13D-1(K) OF THE EXCHANGE ACT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of common stock, par value \$.10 per share of Biota Pharmaceuticals, Inc..

Date: February 12, 2013

Renaissance Technologies LLC

By: Mark Silber

Executive Vice President

Renaissance Technologies Holdings Corporation

By: Mark Silber Vice President

Page 8 of 8 Pages